GHRP-2 treatment in vitro modified pituitary cell expression of GH, pit-1 transcription factor, GHRH receptor, and GHS receptor — revealing how GH secretagogues reprogram pituitary cells for sustained responsiveness.
Key findingIn-vitro GHRP-2 treatment altered pituitary somatotroph expression of GH, Pit-1 transcription factor, GHRH-R, and GHS-R at mRNA and protein levels, de
What the researchers found
In-vitro GHRP-2 treatment altered pituitary somatotroph expression of GH, Pit-1 transcription factor, GHRH-R, and GHS-R at mRNA and protein levels, demonstrating GH secretagogue-induced pituitary cell reprogramming for enhanced GH-axis responsiveness.
Why it matters
Relevant for ghrp, cjc-1295, hormone-optimization, receptor-signaling.
How the study worked
in-vitro study on ghrp, cjc-1295.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide/biomarker research with clinical implications.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells.
European journal of endocrinology, 150(2), 235-42
Citation
Yan, Ming; Hernandez, Maria; Xu, Ruwei; Chen, Chen. (2004). Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells.. European journal of endocrinology, 150(2), 235-42.